Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple drug cocktail targets tough lung cancer

NCT ID NCT04791839

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a combination of three drugs—zimberelimab, domvanalimab, and etrumadenant—in 30 adults with advanced non-small cell lung cancer who have already been treated with immunotherapy. The goal is to see if the triple therapy is safe and can shrink tumors. The study is currently active but not recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Three-drug combination: zimberelimab, domvanalimab, and etrumadenant
What this could lead to
If successful, this could offer a new treatment option for people with non-small cell lung cancer whose cancer has progressed after prior immunotherapy.
What could go wrong
This is a small, early-phase pilot study with only 30 participants. The combination may cause significant side effects, and it is not yet known if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL CARCINOMA NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.